Arvinas appoints Noah Berkowitz as Chief Medical Officer, replacing Ron Peck

ARVINAS, INC.

Noah Berkowitz, M.D., Ph.D., appointed CMO effective March 18, 2024, succeeding Ron Peck, M.D.
Berkowitz brings 20+ years of experience, most recently as SVP at Bristol-Myers Squibb in hematology.
He will lead clinical development of Arvinas' PROTAC protein degrader programs in oncology and neuroscience.
Former CMO Ron Peck to remain an employee until mid-April 2024 for transition, then eligible for severance.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Noah Berkowitz

chief medical officer

ARVN · ARVINAS, INC.

Effective: 2024-03-18
Filed: March 18, 2024, 7:59 PM ET

On March 18, 2024, Arvinas, Inc., a Delaware corporation (the “Company”), announced the appointment of Noah Berkowitz, M.D., Ph.D., to the role of chief medical officer, effective as of March 18, 2024.

Departed

Ron Peck

chief medical officer

ARVN · ARVINAS, INC.

Effective: 2024-03-18
Successor: Noah Berkowitz
Filed: March 18, 2024, 7:59 PM ET

On March 14, 2024, the Company notified Ron Peck, M.D., the Company’s previously serving chief medical officer, of Dr. Berkowitz’s pending appointment and the reassignment of the responsibilities of chief medical officer to Dr. Berkowitz effective as of March 18, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Noah Berkowitz was appointed as chief medical officer at ARVINAS, INC..

Action: appointed
Role: chief medical officer

Exact text from the filing

On March 18, 2024, Arvinas, Inc., a Delaware corporation (the “Company”), announced the appointment of Noah Berkowitz, M.D., Ph.D., to the role of chief medical officer, effective as of March 18, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Ron Peck departed as chief medical officer at ARVINAS, INC..

Action: departed
Role: chief medical officer

Exact text from the filing

On March 14, 2024, the Company notified Ron Peck, M.D., the Company’s previously serving chief medical officer, of Dr. Berkowitz’s pending appointment and the reassignment of the responsibilities of chief medical officer to Dr. Berkowitz effective as of March 18, 2024.

View on SEC.gov

ARVINAS, INC. filing history →

Source: SEC EDGAR

accession 0001655759-24-000033

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.